INDAZOLE-3-Carboxamides AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/534,601, filed Sep 14, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,697,887 | INDAZOLE-3-Carboxamides and Their Use as Wnt/Beta-Catenin Signaling Pathway Inhibitors In force · Medium confidence UsedRemaining | Biosplice Therapeutics, Inc. | In force | Medium confidence | ||
| US 9,802,916 | INDAZOLE-3-Carboxamides and Their Use as Wnt/Beta-Catenin Signaling Pathway Inhibitors In force · Medium confidence | Biosplice Therapeutics, Inc. | In force | Medium confidence | ||
| US 10,464,924 | INDAZOLE-3-Carboxamides and Their Use as Wnt/B-Catenin Signaling Pathway Inhibitors In force · Medium confidence | Biosplice Therapeutics, Inc. | In force | Medium confidence | ||
| US 11,066,388 | INDAZOLE-3-Carboxamides and Their Use as Wnt/B-Catenin Signaling Pathway Inhibitors In force · Medium confidence | Biosplice Therapeutics, Inc. | In force | Medium confidence | ||
| US 11,780,823 | INDAZOLE-3-Carboxamides and Their Use as Wnt/B-Catenin Signaling Pathway Inhibitors In force · Medium confidence | Biosplice Therapeutics, Inc. | In force | Medium confidence | ||
| US 9,221,793 | INDAZOLE-3-Carboxamides AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS In force · Medium confidence | Biosplice Therapeutics, Inc. | In force | Medium confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.